SC-006 / AbbVie - LARVOL DELTA

Molecular Characterization of Clostridium botulinum Isolates from Sichuan Province, China (1990-2024). (PubMed, Foodborne Pathog Dis) - "All strains belonging to Group I (SC001, SC002, SC003, SC006, and SC009) were assigned to five totally different recognized ST types (ST-2 to ST-51). In addition, analysis of BoNTs subtypes demonstrated that the types of BoNTs causing botulism in Sichuan were mainly types A, B, and E. Among them, some rare subtypes of BoNT reported for the first time in China, such as BoNT/B4, BoNT/E12, and BoNT/A5(B3), and no specific subtypes were predominant in the botulism incidents. This study is critical for disease surveillance and early warning systems, while also providing a basis for food safety regulation, clinical diagnosis, and treatment in the future."

Journal

Beyond cold chain: Exploring bacterial-viral interactions and disinfection strategies for norovirus persistence on organic lettuce under temperature fluctuations. (PubMed, J Hazard Mater) - "Transmission electron microscopy (TEM) and molecular docking analysis showed MNV-1 particles binding to HBGA-like substances in SEPS-SC006, potentially enhancing viral resistance. Overall, temperature fluctuations and bacterial-viral interactions affected MNV-1 survival, and the combination of UV and ClO2 offers a promising approach for ensuring fresh produce safety throughout the food cold chain."

Journal

[VIRTUAL] First-in-human clinical trial of SC-006, a RNF43 targeted antibody-drug conjugate, as a monotherapy and in combination with budigalimab in patients with advanced colorectal cancer (AACR-II 2020) - P1 | "SC-006 dose escalation was limited by thrombocytopenia observed below the predicted efficacious dose, leading to study termination."

Clinical • Combination therapy • IO biomarker • Monotherapy • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • RNF43

"Awesome recruitment site visits to a couple of fantastic #ICUs ⁦@VCUHealth⁩ and ⁦@sentarahealth⁩/⁦@EVMSedu⁩. #FutureIsBright #CellDirectedTherapy #SCD006 #ClinicalTrials ⁦@SeaStarMedical⁩ ⁦@Nasdaq⁩ $ICU" (@chungk1031)

Clinical

""Vision without execution is hallucination." - Thomas Edison #CellDirectedTherapy #SCDHDEinPeds #SCD006 $ICU @SeaStarMedical" (@chungk1031)

"Time to get to work! #SCDisCellDirectedTherapy #CDET (Cell Directed Extracorporeal Therapy) #SCDHDEforPeds #SCD006 $ICU" (@chungk1031)

Proteiniclasticum aestuarii sp. nov., isolated from tidal flat sediment, and emended descriptions of the genus Proteiniclasticum and Proteiniclasticum ruminis. (PubMed, Int J Syst Evol Microbiol) - "nov. is proposed, with the type strain SCR006 (=KCTC 25245= JCM 34531)."

Journal • CAT

SC006 - Complexities and Complications: Case-based Conversations in Mechanical Thrombectomy (ISC 2022) - "These cases will highlight real-world issues we face with some thrombectomy patients in the angio suite. Each case will be 15 minutes total with various issues presented and then a 5 minute networking session."

Clinical • Cardiovascular

A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer (clinicaltrials.gov) - P1; N=29; Completed; Sponsor: AbbVie; Active, not recruiting ➔ Completed; Trial completion date: Dec 2020 ➔ Mar 2019; Trial primary completion date: Jul 2020 ➔ Mar 2019

Clinical • Combination therapy • Trial completion • Trial completion date • Trial primary completion date

A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer (clinicaltrials.gov) - P1; N=29; Terminated; Sponsor: AbbVie; Completed ➔ Terminated; Strategic considerations

Clinical • Combination therapy • Trial termination

A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer (clinicaltrials.gov) - P1; N=29; Active, not recruiting; Sponsor: AbbVie; Recruiting ➔ Active, not recruiting; N=108 ➔ 29

Enrollment change • Enrollment closed

Newly added product (AbbVie Press Release) - P1, Colorectal Cancer

Pipeline update